RE:Just Some Food for ThoughtNice work Redatnight. 4 things I would change: 1) 2020- I assume you are referring to arriving at peak revenue by 2020. The market will attach a valuation based on potential peak revenue long before 2020. They will also attach a growth multiple if they see potential for off label, EU approval and sales etc. 2) Berendt said doses were going to be $3000, and then at the AGM stated that $4000 was possible. 3) Profit margin is off. We have our own factory to manufacture, and has been stated on numerous occasions; it is a very high margin drug. Even if a marketing partner is brought in @50% of revenue, our profit would likely be over 30-35%. 4) lastly you are quoting share prices in Canadian and all revenue and valuations will be in USD. Thanks for you insight. It is a nice change from the mud slinging gibberish on this BB.